

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LUCAS et al.

Serial No. 09/779,703

Filed: February 9, 2000

Title: TNF-DERIVED PEPTIDES FOR USE IN TREATING OEDEMA

Assistant Commissioner for Patents  
Washington, DC 20231

Atty Dkt. 2551-55

C# M#

Group Art Unit: Unassigned

Examiner: Unassigned

Date: October 23, 2002

Sir:

**RESPONSE/AMENDMENT/LETTER**  
This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number  
previously paid for 20 (at least 20) = 0 x \$ 18.00

\$ 0.00

Independent claims after amendment 0 minus highest number  
previously paid for 3 (at least 3) = 0 x \$ 84.00

\$ 0.00

\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)

\$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)

\$ 0.00

\$ 0.00

Terminal disclaimer enclosed, add \$ 110.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 0.00

-\$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract  
☐ Applicant claims "small entity" status. ☐ Statement filed herewith

\$ 0.00

\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)

0.00

Assignment Recording Fee (\$40.00)


Other: Response; Notice to Comply (10/10/02); Copy of Preliminary Amendment (2/9/01); Copy of Letter (2/9/01); Copy of Post Card Receipt (2/9/01); Copy of Amendment (9/25/02); Copy of Notice to File Corrected Application Papers (7/25/02); Copy of Post Card Receipt (9/25/02)

**TOTAL FEE ENCLOSED \$ 0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:plb

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 



09/779,703 ISSUE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

LUCAS et al.

Atty. Ref.: 2551-55

Serial No. 09/779,703

Group: Unassigned

Filed: February 9, 2001

Examiner: Unassigned

For: TNF-DERIVED PEPTIDES FOR USE IN TREATING OEDEMA

\* \* \* \* \*

October 23, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE**


Responsive to the Notice to Comply dated October 10, 2002 (copy attached), the Office is requested to appreciate that a Sequence Listing, as required by the Rules, was filed February 9, 2001 with the Preliminary Amendment requesting entry of the same. A copy of the Preliminary Amendment dated February 9, 2001, a copy of the Letter (i.e., Statement) filed February 9, 2001, indicating that the paper and computer readable copies of the Sequence Listing are the same and that no new matter was added, and a copy of the undersigned's Post Card receipt from the filing of February 9, 2001, are attached. Moreover, a copy the filing of February 9, 2001, was re-submitted with the Amendment of September 25, 2002, in response to the Notice to File Corrected Application Papers mailed July 25, 2002. A copy of the undersigned's Amendment of September 25, 2002,

the Notice of July 25, 2002, and the undersigned's Post Card receipt from the filing of September 25, 2002, are attached.


The Office is requested to contact the undersigned if anything further is required. The undersigned submits the Rules relating to the Sequence requirements have been complied with. Specific and particularized Notice of any deficiency in this regard is requested along with an opportunity to supply any further needed information.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:   
B. J. Sadoff  
Reg. No. 36,663

BJS:plb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE

0971703 10 Page 1 of 2

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/779,703	02/09/2001	Rudolf Lucas	2551-55

NIXON & VANDERHYE P.C.  
8th Floor  
1100 North Glebe Road  
Arlington, VA 22201

CONFIRMATION NO. 6732

FORMALITIES LETTER



\*OC000000008936648\*

Date Mailed: 10/10/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

COPY

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/779,703	02/09/2001	Rudolf Lucas	2551-55 -BJS

DOCKETED

CONFIRMATION NO. 6732

NIXON & VANDERHYE P.C.  
8th Floor  
1100 North Glebe Road  
Arlington, VA 22201

CLT/MATTER # 2551-55  
MAIL DATE 7/25/02  
DUE DATE Sept 25, 2002  
FINAL DEADLINE Feb 25, 2003  
DOCKETED BY MSS/par

## FORMALITIES LETTER



\*OC000000008519198\*

Date Mailed: 07/25/2002

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

*Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:


- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

COPY

  
\_\_\_\_\_  
Customer Service Center

Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE



COPY

Serial No.: 09/779,703  
Inventor/s: LUCAS et al.  
Title: TNF-DERIVED PEPTIDES FOR USE IN TREATING  
OEDEMA

C#/M#: 2551-55  
Atty: B. J. Sadoff  
Date: Sep. 25, 02



**XX Amendment**

**\$0.00 Total Fee Enclosed**



Other: **Abstract (separate page); Copy of  
Notice to File Corrected Application Papers  
dated July 25, 2002; Copy of Post Card Receipt  
dated February 9, 2001; Letter and Paper copy  
of Sequence Listing dated February 9, 2001**





COPY

CONTINUATION OF  
Serial No.: PCT/EP99/05806 Atty: BJS  
Applicant: LUCAS et al Date: 02-09-01  
Title: TNF-Derived Peptides Client: 25.51  
for use in treating edema Ref: 55  
X Amendment & amended pages 4-8 marked up  
16 Pages Specification & claims pages 4-8  
10 Claims (20 as amended)  
6 Sheets Drawings: Formal Jc929 U.S. PTO  
Informal 09/779703  
    Declaration (     Pages)  
    Assignment  
X Priority Document IDS, PTO-1449 & CITATIONS  
    Base Issue Fee Transmittal  
    Fee (Check)

Other: letter attaching paper and  
computer readable copies of  
3 page sequence listing